ADAP - Adaptimmune stock soars ~15% as Guggenheim upgrades rating to Buy

• Adaptimmune Therapeutics ( NASDAQ: ADAP ) stock rose ~17% on Tuesday after Guggenheim upgraded the U.K.-based company's stock to Buy from Neutral.
• The SA Quant Rating on the shares is Buy , which takes into account factors such as Momentum, Profitability, and Valuation among others. ADAP has an A- factor grade for Growth and C+ score for Profitability. The average Wall Street Analysts' Rating is also Buy , wherein 2 out of 6 analysts tag the stock as Strong Buy, 3 see it as Hold and 1 as Sell.
• However, in the past one year ADAP has fallen ~55% , see chart here .

For further details see: